Search This Blog

Thursday, February 13, 2020

Blueprint Medicines EPS beats by $0.41, beats on revenue

Blueprint Medicines  (NASDAQ:BPMC): Q4 GAAP EPS of -$1.35 beats by $0.41.
Revenue of $51.53M (+4902.9% Y/Y) beats by $25.53M.
Press Release
https://seekingalpha.com/news/3541618-blueprint-medicines-and-nbsp-eps-beats-0_41-beats-on-revenue
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)